PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4(+) T cell transcriptomal molecular signatures. by Hoft, D. F. et al.
Boston University
OpenBU http://open.bu.edu
BU Open Access Articles BU Open Access Articles
2017-08-30
PO and ID BCG vaccination in
humans induce distinct mucosal
and systemic immune respon...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version
Citation (published version): D.F. Hoft, M. Xia, G.L. Zhang, A. Blazevic, J. Tennant, C. Kaplan, G.
Matuschak, T.J. Dube, H. Hill, L.S. Schlesinger, P.L. Andersen, V.
Brusic. 2017. "PO and ID BCG vaccination in humans induce distinct
mucosal and systemic immune responses and CD4(+) T cell
transcriptomal molecular signatures.." Mucosal Immunol,
https://hdl.handle.net/2144/24316
Boston University
OPEN
PO and ID BCG vaccination in humans induce
distinct mucosal and systemic immune responses
and CD4þ T cell transcriptomal molecular
signatures
DF Hoft1,2, M Xia1, GL Zhang3, A Blazevic1, J Tennant1, C Kaplan4, G Matuschak4, TJ Dube5, H Hill5,
LS Schlesinger6, PL Andersen7 and V Brusic3,8
Protective efficacy of Bacillus Calmette-Gue´rin (BCG) may be affected by the methods and routes of vaccine
administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration
of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated
with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-c
production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses
(TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate
preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination,
CD4þ memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination
(Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray
transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing
thePOand IDBCGvaccinated groups byGSEA analysis. Future correlation analyses between specific gene expression
patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine
development.
INTRODUCTION
Over one-third of the world’s population is currently infected
with Mycobacterium tuberculosis (Mtb), and 41.5 million
individuals die of tuberculosis (TB) each year.1 The current TB
vaccine, the attenuated Mycobacterium bovis strain Bacillus of
Calmette and Guerin (BCG), is effective at preventing
disseminated forms of TB in very young children.2,3 However,
the efficacy in prevention of adult pulmonary TB, the major
form of transmissible disease, at best is only 50%.4 Intradermal
(ID) administration is the major route of BCG vaccination
worldwide, but this vaccination method is unlikely to induce
optimal lung mucosal immunity.5,6 We hypothesize that
combining systemic and mucosal TB vaccinations may induce
not only systemic immunity protective against the worst forms
of disseminated TB disease, but also mucosal immunity
protective against initial TB infection and/or secondary
transmission.
We have initiated a series of BCG vaccination trials with the
overall goal of identifying the major human immune responses
that BCG does and does not induce, and to determine the
immune responses new and improved TB vaccines must
stimulate to provide better protection than ID BCG. An
additional goal of our ongoing work is to investigate the
possibility that mucosal BCG vaccination can uniquely induce
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immune responses relevant for optimal lung mucosal TB
immunity. Because oral (PO) BCG vaccination was the original
route used by Calmette and Guerin,3 and millions of persons
have been vaccinated with BCG orally in Brazil over the past 50
years,7 there are considerable safety data to support the use of
PO BCG in humans.8 In addition, activated memory T and B
lymphocytes have been shown to develop differentiation
programs allowing them to circulate and home to multiple
different mucosal tissues, indicating that PO vaccines could
induce increased immunity at distant mucosal sites.9–11
Administration of ID and/or PO BCG in ongoing research
protocols allows for comparison of the mucosal and systemic
TB-specific immune responses induced with current and
alternative methods of vaccine administration. We report here
the first detailed analysis of human immune responses induced
by ID and/or PO BCG. Our results support the hypothesis
that a combined ID and PO BCG vaccination approach could
induce the best combination of mucosal and systemic TB
immunity.
Recent studies have used systems biology approaches to
obtain a global picture of the immune responses to vaccination
in humans.12–16 Systems biology tools have enabled the
identification of early innate signatures that predict the
immunogenicity of vaccines, and identification of potentially
novel mechanisms of immune regulation. In this work we have
taken a novel systems biology approach focusing on the
identification of gene expression networks involved in the
induction of CD4þ T cells, critically important for optimal
mucosal and systemic TB immunity. Our preliminary data
indicate that PO and ID BCG induce distinct profiles of
molecular signatures, suggesting that more detailed analyses
will identify genes and/or gene networks that should be
differentially targeted by vaccines designed to induce both
optimal mucosal and systemic TB immunity.
RESULTS
Summary of enrollment, safety and determination of
optimal PO BCG danish dose
All 16 subjects enrolled into the initial Danish BCG PO dose
escalation trial completed 6 months of observation, and none
developed any significant adverse events. Optimal BCG-
specific blood T cell IFN-g responses and nasal wash Mtb
LAM-specific secretory IgA (sIgA) responses post-vaccination
were detected in subjects given 2 108 colony forming units
(cfu) of Danish BCGPO (data not shown). In the double-blind,
placebo controlled trial, 60 subjects were randomized among
the groups A-F (10/group; see Figure 1 and Supplementary
Figure 1 online). In addition, 8 subjects were enrolled into an
open label arm (group G) who received 2106 cfu of
Connaught BCG ID. All 68 subjects received their initial
BCG vaccinations as planned, 63 subjects were followed for
at least 6 months after the initial vaccinations, 43 received
second vaccinations 1 year later (20 received BCG
revaccination and 23 received placebo 1 year after the first
vaccinations), and 48 completed 2 years of follow-up. The
number of drop outs during the second year reduced sample
sizes to less than optimal for detection of significant increases in
the immunogenicity parameters induced by the booster BCG
vaccinations. Therefore, for most immunogenicity results
presented below, groups AþB, CþD and Eþ F were
combined based on the type of BCG vaccination given at
the beginning of the trial. Only limited comparisons between
group G and the other groups are shown because of the smaller
sample size in group G, further reduction in sample size due to
drop outs, and the lack of meaningful differences detected
between groups AþB (given ID Danish BCG) and group G.
However, some group G subjects were recruited into a BAL
study and these results are presented alongwith the results from
all other groups. No deaths or other significant adverse events
(SAE) occurred during these trials. There were no severe AEs
caused by vaccination except for in 1 subject (ID BCG alone/
Group A) who developed transient erythema at the ID
vaccination site graded as severe by size. This severe graded
erythema did not interfere with the subject’s normal activities
and was not associated with any other symptoms. There were
eleven moderate related unsolicited adverse events, nine of
which occurred post vaccination 1. Seven of these events,
experienced by subjects in all Groups except PO BCG alone
(groups CþD), were described as continued reactogenicity.
The remaining four events, experienced by subjects in ID BCG
alone, PO BCG alone and combined ID and PO groups (1
subject in each of the following groups: A, B, C and E), included:
appetite loss, upper respiratory infection, URI and mandibular
pain. Overall, these results indicate that no safety signals were
detected in this small trial.
Mtb-specific lymphoproliferative responses were induced
most strongly by ID BCG
Supplementary Figure 2A. presents the mean±s.e. peripheral
blood lymphoproliferative responses induced in all subjects
regardless of group assignment over the 2 years of follow-up.
BCG significantly increased (Po0.05) Mtb-specific T-cell
A ID BCG/PO Placebo ID Placebo/PO Placebo
B ID BCG /PO Placebo ID BCG/PO Placebo 
C ID Placebo/PO BCG ID Placebo/PO Placebo
D ID Placebo/PO BCG ID Placebo/PO BCG
E ID BCG /PO BCG ID Placebo/PO Placebo
F ID BCG /PO BCG ID BCG /PO BCG
Group* Dose 1 Dose 2 (12 m later)
Figure 1 Overview schematic of the clinical trial. Ten subjects
were recruited into each of the groups (A–F), randomized in a double
blind fashion to receive PO vs. ID vs. POþID Danish BCG. An additional
8 subjects were recruited into an open label, ID Connaught BCG
vaccination cohort (to compare ID immunity induced by Danish vs.
Connaught BCG). During year 1 of the trial, groups A and B were identical
(given only ID BCG), groups C and D were identical (given only PO BCG),
and groups E and F were identical (given both ID and PO BCG).
Blood, tear, nasal wash and stool samples were collected at 9 different
time points (pre-vaccination, and 1 week, 2months, 6months, 12months,
12 months plus 1 week, 14 months, 18 months and 24 months post-
vaccination). *10 volunteers/group
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responses that persisted for at least 2 years after vaccination.
Lymphoproliferative responses specific for a single major Mtb
secreted protein (Ag85B), and for all Mtb secreted proteins
present in culture filtrates (CF) of logarithmically replicating
extracellular Mtb organisms in vitro, were both significantly
increased post-vaccination. Figure 2 shows lymphoproliferative
responses induced by these same Mtb antigen preparations
(Ag85B andMtb CF in Figure 2a and b, respectively) during the
first year post-vaccination for subjects given ID BCG alone
(groups AþB), POBCG alone (groups CþD) and both ID and
POBCG (groupsEþ F).Median responses for each are shown at
the different time points. These latter results demonstrate that all
three BCG vaccination strategies resulted in at least some
increasedMtb-specific lymphoproliferative responses. However,
only subjects given ID BCG (with or without PO BCG)
developed significantly higher post-vaccination responses.
Mtb-specific IFN-c-producing T cells were most strongly
induced by ID BCG
Supplementary Figure 2B online. presents the mean±s.e.
peripheral blood IFN-g ELISPOT responses induced, as an
overall assessment ofMtb-specific type 1 immune responses, in
all subjects regardless of group assignment over the 2 years of
follow up. BCG vaccination also significantly increased Mtb-
specific type 1 T cells that persisted for at least 2 years after
vaccination. IFN-g responses specific for the major secreted
protein, Ag85B, and for all Mtb CF secreted proteins, were both
significantly increased post-vaccination. Figure 3 shows IFN-g
ELISPOT responses induced by Ag85B andMtb CF (Figure 3a
and b, respectively) during the first year post-vaccination for
subjects given ID BCG alone (groups AþB), PO BCG alone
(groups CþD) and both ID and PO BCG (groups Eþ F).
Median responses are depicted for each group at the different
time points. It can be seen that only the groups given ID BCG
(with or without PO BCG) developed significantly increased
Mtb-specific IFN-g responses post-vaccination (by Wilcoxon
matched pairs test). Table 1 further confirms these results
demonstrating that significantly increased proportions of
subjects in the groups given ID BCG developed positive
IFN-g responses post-vaccination (defined as a response
greater than the mean plus 2 SE of all baseline responses;
all significant differences detected are presented). In 5 different
comparisons of antigen-specific responses at both early and late
time points, ID groups had significantly higher proportions of
responders than PO recipients. Furthermore, 2 comparisons
indicated that combined ID plus PO BCG vaccination induced
higher proportions of positive IFN-g responses than PO BCG
alone, providing additional support for the conclusion that ID
BCG induces stronger systemic TB-specific immunity than PO
BCG. Two comparisons indicated that ID BCG alone induced
higher proportions of responders than ID plus PO, perhaps
because more T cells were recruited out of the blood and into
the peripheral mucosal tissues, due to the higher doses of BCG
given PO (40-fold more BCG cfu were used for PO compared
with ID vaccination).
Mucosal Mtb-specific sIgA responses were most strongly
induced by PO BCG
We studied Mtb-derived lipoarabinomannan (LAM)-specific
sIgA in stool, nasal wash and tear samples pre- and post-
vaccination, as a marker of BCG-induced mucosal immunity.
As reported previously,17 we were unable to measure vaccine-
induced, LAM-specific sIgA responses in stool samples,
presumably due to dilutional and proteolytic effects known
to occur as sIgA is transported to the distal gut. However, in
nasal wash samples (Figure 4a) and tears (Figure 4b.), relative
increases inMtb LAM-specific sIgAwere seen post-vaccination
in the groups that had received PO BCG, but not in the group
given only ID BCG. These relative increases compared to Day 0
seen in the PO BCG vaccination groups did not achieve
statistical significance (by Wilcoxon matched pairs tests),
probably because of the small sample sizes. However, our
previous data generated from 2 PO BCG dose escalation trials
demonstrated that PO BCG can induce TB-specific sIgA
responses.9,17 These results indicate that PO BCG can uniquely
induce mucosal immune responses relevant for TB immunity.
*
**
**
** **
*
*
a b
Figure 2 Blood lymphocyte Mtb-specific lymphoproliferation assay results. Heparinized whole-blood samples were diluted with medium 10-fold and
stimulated with either themajor secreted Ag85 protein (a) or Mtb culture filtrate (CF, complex lysate of all Mtb antigens secreted by exponentially growing
organisms), (b), and tritiated thymidine incorporationmeasured on day 7.Median values for each group (N¼20) are shown for each timepoint. *Po0.05,
**Po0.01 by Wilcoxon-matched pairs testing compared with pre-vaccination responses.
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Mtb-specific T cells were increased in the lungs of subjects
given PO BCG
As a sub-study to the main BCG vaccination protocol, we
performed BAL on 16 consenting subjects (5 received IDDanish
BCG alone, 3 received ID Connaught BCG alone, 6 received PO
DanishBCGalone, and 2 receivedboth IDandPODanishBCG),
1–12 months after the initial vaccinations. BAL cells were
collected and studied by both IFN-g ELISPOT and flow
cytometric methods. We stimulated the BAL cells with
Ag85B peptides, purified protein derivative (PPD) and live
BCG as previously described.18 The results from two subjects
were excluded from analysis because the low viability of
recovered BAL cells resulted in no response even to the positive
controls, and the fewnegative values obtainedwere replacedwith
‘0’. Figure 5a shows that similar circulating blood lymphocyte
IFN-g responses were detected comparing all subjects given ID
BCG alone and all subjects given PO BCG with or without ID
BCG. Despite similar circulating blood lymphocyte responses,
Figure 5b demonstrates that up to sixfold more Mtb-specific
T cells were found in the airways of subjects who received PO
BCG compared with subjects given only ID BCG. Figure 5a,b
present separate symbols for individual subjects given IDDanish
BCG only (blue circles), ID Connaught BCG only (purple
triangles), PODanish BCG only (orange circles) and ID plus PO
Danish BCG (green squares). Trends for increased immuno-
genicity of ID Connaught BCG compared with ID Danish BCG,
and increased immunogenicity of ID plus PO Danish BCG
compared with PO Danish BCG alone, can be observed both
with blood lymphocytes and BAL cells. However, these trends
(additional variables) do not alter our overall conclusions that ID
BCG induced similar or stronger blood responses than POBCG,
while PO BCG induced stronger BAL responses. Furthermore,
both ID BCG alone and PO±ID BCG, induced significant
increases in Mtb-specific blood responses compared with the
matchedmedium rest background responses for the same group,
while only PO±ID BCG induced significant increases in Mtb-
specific BAL responses compared withmedium rest (Po0.05 by
Wilcoxon matched pairs testing).
We also studied T-cell surface expression of a4b1 and
CXCR3, known to be involved in immune trafficking to the
lung. In Figure 5c., we show that the proportions of circulating
blood CD8þ T cells expressing the integrin complex a4b1were
significantly increased in subjects vaccinated with PO BCG. In
Figure 5d., we demonstrate that significantly increased
proportions of lung CD4þ and CD8þ T cells in subjects
given PO BCG expressed CXCR3, a chemokine receptor
previously implicated in lung trafficking of antigen-specific T
cells.19,20 These results indicate that PO BCG can increase the
numbers of circulating blood T cells that express a4b1
suggesting that assessment of circulating a4b1þ T cells
may be useful as a biomarker of the induction of mucosal
responses. In addition, the expression of CXCR3 on lung
airway T cells may be useful as a biomarker of recent lung
trafficking.
*
**
**
**
a b
*
Figure 3 Blood lymphocyteMtb-specific IFN-gELISPOTassay results. Freshly harvestedPBMCwere studied in IFN-gELISPOTplates stimulatedwith
an Ag85 overlapping peptide pool (a) or Mtb CF (b). Median values for each group (N¼20) are shown for each time point. *Po0.05, **Po0.01 by
Wilcoxon matched pairs testing compared with pre-vaccination responses.
Table 1 Significant differences in proportions positive in
IFN-g ELISPOT assays
% Responders Fisher’s exact test P value
Antigen Day ID PO POþ ID ID vs. PO ID vs.
POþ ID
POþ ID
vs. PO
rAg85B 180 35 6 0 0.048 0.011 1.000
rAg85B 730 33 0 15 0.028 0.412 0.480
Ag85Bp 7 75 41 42 0.050 0.054 1.000
Ag85Bp 56 65 37 28 0.113 0.028 0.728
Ag85Bp 730 44 0 15 0.010 0.129 0.480
Mtb CF 7 35 12 47 0.137 0.523 0.031
Mtb CF 56 55 26 67 0.105 0.522 0.022
Mtb CF 421 39 0 23 0.024 0.452 0.220
Abbreviation: BCG, Bacillus Calmette-Gue´rin.
All significant differences comparing groups for responses to all antigens, at all
timepoints pre- and post-vaccination are listed here. All statistically significant
differences found involved greater responses in the groups given ID BCG compared
with the group given only PO BCG, or responses in the group given ID BCG alone
being higher than in the group given POþ ID BCG. Corrections for multiple
comparisons were not done because of the small sample sizes.
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CutaneousPPD-specificDTH responseswere inducedonly
by ID BCG
We previously reported that PO BCG skewed Mtb-specific T
cells toward mucosal homing and reduced cutaneous homing
manifest as significantly reduced PPD-specific delayed-type
hypersensitivity (DTH) reactivity in PO compared with ID
BCG recipients.21 At the end of the 2 years of observation, we
performed 5 TU PPD skin tests and found, as reported before,
that there was a significantly greater proportion of subjects
given ID BCG with positive PPD responses (X10mm)
*P<0.05
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Figure5 Bronchoalveolar lavage (BAL) sub-study to identify lungTB-specific T cells. A sub-study targeting subjects enrolled in theparentDMID-01-351
trial was conducted involving a single post-vaccination BAL procedure and blood sample obtained the same day. (a,b) show IFN-g ELISPOT results for
PBMCandBAL cells, respectively. Box-plotswith scatter plot overlay are presented for PBMCandBAL cells. (c) shows flowcytometric studies identifying
the percentages of CD4þ and CD8þ T cells expressing a4b1 in PBMC. (d) Flow cytometric studies identifying the percentages of CD4þ and CD8þ
T cells expressing CXCR3 among BAL cells. *Po0.05, **Po0.01 by Mann–Whitney testing compared with group responses.
Figure 4 Mtb-specific secretory IgA results. Nasal wash (a) and tear (b) samples were obtained and studied in Mtb lipoarabinomannan (LAM)-coated
ELISA plates. In both cases, subjects given PO BCG were found to have higher Mtb LAM-specific sIgA detected. Each group (N¼20).
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compared with subjects given PO BCG (9/18 vs. 0/13,
respectively, Po0.05 by Fisher’s exact two-sided test). Only
3 of 13 given ID and POBCGhad positive PPD responses at the
end of the trial, also consistent with negative effects of PO BCG
on PPD-specific DTH. These results confirm our previous
studies indicating that ID and PO BCG program vaccine-
induced T cells for differential cutaneous vs. mucosal homing
programs.22
ID and PO BCG-induced distinct memory CD4þ T cell
transcriptomal responses
Because we found unique mucosal and systemic immune
responses induced by PO and ID BCG, respectively, we
performed additional studies of the CD4þ T-cell transcrip-
tomes present post-vaccination. We hypothesized that distinct
individual genes and gene networks important for differential
mucosal and systemic immune responses would be induced by
the different routes of vaccination. We compared vaccine-
induced transcriptomal changes at the predicted peak of post-
vaccination T-cell activation (Day 7 post-vaccination), and at
an early memory time point (Day 56 post-vaccination). We
focused on comparisons of transcriptomes at Day 7 directly
ex vivo without further in vitro stimulation to restrict our
studies to the ongoing responses induced in vivo. However, at
Day 56 we assumed that memory T cells would be past the peak
of in vivo activation and require further stimulation in vitro to
identify differences induced by PO and ID BCG vaccination.
Figure 6 shows the results of our preliminary transcriptomal
investigations. Figure 6a shows individual heat maps for the
top 100 most significantly altered genes comparing Day 0 and
Day 7 responses directly ex vivo (without re-stimulation with
BCG-infected dendritic cells), inCD4þ Tcells from the POand
ID BCG vaccinated subjects. The Venn diagram in Figure 6b
demonstrates that the Day 7 differentially expressed genes were
largely distinct comparing subjects given PO and ID BCG
vaccination. Figure 6c shows individual heat maps for the top
100 most differentially expressed genes comparing Day 0 and
Day 56 responses after in vitro re-stimulation with BCG-
infected autologous dendritic cells, in CD4þ T cells from PO
and ID BCG vaccinated subjects. The Venn diagram in
Figure 6d demonstrates that similar to Day 7 responses, the
Day 56 differentially expressed genes were largely distinct
comparing subjects given PO and ID BCG vaccination. These
results provide strong evidence that PO and ID BCG induce
very different transcriptomal patterns in human CD4þ T cells
important for differential induction and persistence of mucosal
and systemic TB immunity.
DISCUSSION
Our major original hypothesis was that the combination of
mucosal and systemic BCG vaccination would induce the
optimal combination of mucosal and systemic TB-specific
immune responses important for TB protective immunity.
Overall the results of this trial support this conclusion by
indicating that PO BCG-induced stronger mucosal responses
and ID BCG-induced stronger systemic immune responses.
Furthermore, the combination of PO and ID BCG resulted
increases in both mucosal and systemic immune responses.
In addition, no major safety signals were identified, further
supporting the rationale for additional studies of mucosal BCG
vaccination.
ID BCG vaccination induced stronger and more reprodu-
cible systemic immune responses compared with PO BCG
vaccination. Positive response rates post-vaccination in both
PBMC IFN-g ELISPOT and lymphoproliferative assays, were
greater in subjects given ID compared with PO BCG.
Numerous examples of ID recipients developing significantly
higher response rates than PO recipients were seen in these
assays that measure functional characteristics of systemic
CD4þ T helper type 1 responses thought to be critical for TB
protective immunity. In Figure 3a, groups Eþ F are shown to
have increased responses at Day 7, but then the responses are
decreased. The increased responses at Day 7 in subjects given
both POþ ID BCG suggest early induction of T cells, but these
induced T cellsmay traffic tomucosal peripheral sites leading to
decreased numbers of T cells circulating in the blood.
PO BCG vaccination induced stronger/more reproducible
mucosal secretory IgA responses compared with ID BCG
vaccination. Positive response rates in the LAM-specific
secretory IgA responses detected in nasal wash and tear
specimens collected post-vaccination were higher in subjects
given PO BCG compared with ID BCG alone. These relative
increases compared to Day 0 seen in the PO BCG vaccination
groups did not achieve statistical significance (by Wilcoxon
matched pairs tests), probably because of the small sample sizes.
However, combined with our previously published data from
PO dose escalation trials reporting that PO BCG can
significantly increase TB-specific sIgA responses,9,17 our
current results further support the unique induction of nasal
wash and tear sIgA responses by PO BCG. In contrast, despite
these results, the stool secretory IgA responses were not
increased in PO BCG recipients. Initially, this might seem
surprising because the PO BCG delivery is expected to induce
gut mucosal immunity after being taken up by mucosal
immune inductive sites within the Peyer’s patches lining the
small bowel. However, our current negative results for stool
secretory IgA after PO BCG are similar to the findings in our 2
previous PO BCG trials, in which we have not detected post-
vaccination increases in stool secretory IgA responses. Stool
contains a high content of proteases which can degrade
secretory IgA over time,23 and themethod for collection of stool
samples results in much higher dilutions of stool secretions
compared with the methods for collection of nasal washes and
tears.17 Therefore, stool studies are the least reliable for
detection of mucosal immune responses induced by vaccina-
tion compared with other mucosal secretions. The detection of
increased secretory IgA responses in nasal washes and tears
document mucosal immune responses induced by PO BCG,
and also demonstrate that these mucosal immune responses
were able to traffic to distant mucosal tissues including those
lining the upper respiratory track, possibly relevant for
protection against TB infection.
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The comparison of BAL cell and PBMC responses in subjects
recruited for the BAL sub-study demonstrated that PO BCG
also induced highly significant increases in T-cell surface
markers important for lymphocyte trafficking to the lung.
Highly reproducible and significant increases in both BAL
T cell expression of CXCR3 and PBMC T cell expression of the
a4/b1 integrin complex were induced in subjects given POwith
or without ID BCG, compared with those given ID BCG alone.
These T cell surface markers have been shown in numerous
model systems to be important for the trafficking of CD4þ
Th1 cells and CD8þ T cells to the lungs.6,11,20,24,25 Both CD4þ
Th1 andCD8þ T cells specific for TB antigens are thought to be
critically important for protective TB immunity.6 Therefore,
the BAL/PBMC sub-study results indicate that PO BCG
induces the potential for more T cells protective against TB to
traffic to the site of initial infection.
Also, evident in the BAL/PBMC sub-study, PO BCG with or
without ID BCG led to higher BAL overall TB-specific T cell
responses in the lungs compared with persons given only ID
BCG. The numbers of antigen-specific BAL T cells producing
IFN-g after in vitro stimulation with Ag85, PPD and BCGwere
four- to sixfold increased in persons given PO with or without
ID BCG. The fact that reproducible increases were detected
with all TB antigens used to stimulate T cell responses in vitro,
Figure 6 CD4þ T-cell transcriptomal differences induced by PO and ID BCG. Memory CD4þ T cells were purified from PBMC collected pre-
vaccination, 7 days post-vaccination and 56 days post-vaccination from 11 subjects (4 given PO BCG and 7 given ID BCG). Autologous dendritic cells
(DC) were generated from blood monocytes and infected or not with BCG. The three different serial memory CD4þ T-cell populations were cultured for
24 h with uninfected or BCG-infected DC, and then RNA collected for Illumina BeadArray transcriptomal analysis. (a) Heat maps for the top 100 altered
genes comparingDay7andDay0directex vivo responses (PON¼ 4and IDN¼ 7). (b) This panel shows that only threeof the top altered genes detected
at Day 7 were the same in PO vs. ID BCG recipients. (c) Heat maps for the top altered genes comparing Day 56 and Day 0 after re-stimulation with
BCG-infected DC (PON¼4 and IDN¼ 7). (d) This panel shows that only 2 of the top altered genes detected at Day 56 were the same in PO vs. ID BCG
recipients.
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further supports our conclusion. Despite the reproducible
increases in TB-specific T cells in subjects given PO BCG, the
responses in PBMC obtained from these subjects on the same
day as the BAL procedures were similar in subjects given ID
BCG alone and subjects given PO BCG with or without ID
BCG. These latter results provide additional support for the
conclusion that PO BCG uniquely induced increased TB-
specific T cells with lung-trafficking potential. The BAL
procedures were done 1–12 months post-vaccination in these
subjects, further indicating the robustness of our findings.
These results, combined with the sIgA and lymphocyte
trafficking molecule expression results discussed above,
provide complementary evidence that PO BCG more strongly
induces multiple mucosal immune responses relevant for
protective mucosal TB immunity.
We have hypothesized previously21 that PO BCG induces
differential T-cell trafficking compared with ID BCG. The
above findings are consistent with this hypothesis. In addition,
the PPD-specific DTH responses detected in subjects at the end
of this trial support our earlier published results,21 indicating
that PO BCG fails to induce PPD-specific DTH responses, and
even may suppress these responses. These results support our
earlier conclusion that PO BCG could provide TB immunity
against initial infection without the induction of PPD-specific
delayed type hypersensitivity that can interfere with detection
of latent TB infection and disease.
The preliminary CD4þ T-cell transcriptomal studies
produced provocative data suggesting that PO and ID BCG
vaccination induce distinct profiles of molecular signatures,
which may explain the differences in mucosal and systemic
immune responses induced. The sample size studied in this
manner needs to be expanded with additional stored PBMC to
further confirm the validity of our conclusions, and to allow for
studies of correlations between the expression of specific genes
and gene sets and the mucosal and systemic immune responses
induced in this trial. This work is currently ongoing.
Further research in this area should focus on at least twomajor
areas to learn how optimal TB-specific mucosal and systemic
immunity can be induced. First, we have only explored one
combined schedule of PO and ID BCG vaccination. Additional
work could investigate the effects of different doses of PO and ID
BCG, different strains of BCG given PO and ID, different
sequences of mucosal vs. systemic BCG vaccination (e.g., first
priming with mucosal vaccination followed at different intervals
by ID vaccination), different routes of mucosal BCG vaccination
(intranasal or aerosolized vaccinations with BCG may induce
even stronger TB-specific lung immunity, although additional
safety concerns would need to be addressed), and mucosal and
systemic vaccinations with newer and potentially more potent
TB vaccines. Second, additional studies investigating the
molecular events which drive the induction of optimal mucosal
and systemic TB-specific immune responses, are needed to allow
further iterative improvements in mucosal and systemic
vaccinations. To this end, the preliminary CD4þ T-cell
transcriptomal studies in subjects given PO vs. ID BCG
vaccination need to be expanded as noted above.
Overall, these results demonstrate that ID BCG induces the
strongest TB-specific systemic immune responses, while PO
BCG induces the strongest TB-specific mucosal immune
responses. Therefore, these results support our original
hypothesis that mucosal and systemic vaccinations with
BCG will induce the optimal combination of mucosal and
systemic immune responses relevant for protection against TB
infection and disease progression. In addition, these results will
greatly facilitate further targeted development of methods for
assessing mucosal and systemic immune responses induced by
other TB vaccines.
METHODS
Subject enrollment, randomization and follow up. Healthy HIV-
negative, HCV-negative, Quantiferon TB-negative adults aged 18–45
years without known TB exposure risks or immunosuppression were
enrolled into 2 separate trials. The first (DMID-99-024) involved a
bridging dose escalation trial of Danish 1331 BCG given orally to 16
subjects at 1 of 3 doses: 2 108 cfu, 2 109 cfu or 2 1010 cfu. The
second trial (DMID-01-351) involved 68 subjects randomized into a
double-blind, placebo-controlled comparison ofDanish orConnaught
BCG given intradermally (ID), orally (PO) or by both routes. Subjects
were randomized toGroupsA-F (10/group) to receiveDanish SSI BCG
or placebo at Day 0 and 1 year later. To explore the BCG strain
specificity of clinical effects and immunogenicity eight volunteers
were enrolled into an open label group given ID Connaught BCG.
Each ID BCG dose included 5 105 cfu, and each PO BCG dose
included 2 108 cfu. IDBCGwas delivered over the deltoid in 0.1ml of
saline. PO BCG was delivered in 60ml of PBS within 15min after the
subject ingested 150ml of oral bicarbonate (0.1M) solution given to
neutralize stomach acid. After drinking the BCG, subjects immediately
ingested an additional 150ml of PBS alone to ensure all BCG was
swallowed. Solicited symptoms were collected for 15 days (Days 0–14)
after each vaccination. Unsolicited adverse events were collected for 2
months after each vaccination. Serious adverse events were collected
through 12 months after the last vaccination. Immediately before
vaccination and at various times after each vaccination (1 week, 2
months, 6 months and 12 months), samples of serum, nasal washes,
tears and stool were obtained for the assessment of IgG and IgA
responses by ELISA. In addition, PBMC were collected at these same
time points pre- and post-vaccination for analyses of lymphoproli-
ferative, cytokine ELISPOT and transcriptomal assays. As a sub-study,
bronchoscopy and bronchoalveolar lavage (BAL) were performed on a
subset of subjects at 1–12 months following the primary and/or
secondary vaccination.
Lymphoproliferation. Whole blood samples were diluted 10-fold with
RPMI and expanded with optimal doses of recombinant Ag85b
protein, Mtb culture filtrate which was derived from the H37Rv strain
and contains most of the secreted proteins from the organism (BEI
Resources), PPD, live BCG, or rested in medium for 7 days at 37 1C in
5% CO2. During the last 10–14 hours, these cultures were pulsed with
tritiated thymidine and cell-incorporated radioactivity measured. The
results are presented as disintegrations per minute (d.p.m.) of
radioactivity.
IFN-g ELISPOT. IFN-g producing cells were identified by ELISPOT
using ImmunoSpot plates (Cellular Technology, Cleveland, OH, USA)
and IFN-g-specific antibodies (BDPharmingen, SanDiego, CA,USA).
PBMC or total bronchoalveolar lavage cells (0.2–1 105 cells per well)
were stimulated with Ag85b peptide pools (1mgml 1), recombinant
Ag85b protein (5 mgml 1), Mtb culture filtrate (5mgml 1, BEI) live
BCG (0.5 MOI) or medium alone for 24 h at 37 1Cwith 5% CO2. Spots
were identified by CTL Analyzer and ImmunoSpot software, version
3.2 (C.T.L.).
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Secretory IgA (sIgA) ELISA. Nasal washes, tears and stool samples
were collected as described previously.17 Immulon 2 plates were coated
with 4 mgml 1 of lipoarabinomannan H37Ra LAM (provided by Dr.
Larry Schlesinger, Ohio State University) diluted in 100% ethanol. The
plates were dried for 3–4 h in a fume hood then washed with PBS plus
0.05% tween 20. Plates were blocked overnight at 4 oC with 1% BSA in
PBS with 0.05% tween 20. Following blocking, the plates were washed
and serum, tear, nasal wash and stool samples were added to duplicate
wells at optimal dilutions predetermined for each type of sample. The
plates were incubated overnight at 4 oC. After washing and the
application of goat anti-human IgG or goat anti-human IgA
horseradish peroxidase (Southern Biotechnology Associates), plates
were incubated for 1 h at room temperature in the dark. Then plates
were washed and the ABTS substrate (Kirkegaard & Perry, Gai-
thersburg, MD), was added. After the plates were incubated 20min at
room temperature, absorbance was read at 405 nm.
Bronchoalveolar lavage. A sub-study was conducted to analyze T
cells in the lungs of subjects vaccinated with BCG ID and/or PO.
Subjects were recruited for a single bronchoscopy with BAL 1–12
months post-vaccination. A blood sample for density-gradient
purification of PBMCwas obtained on the day of the BAL procedure in
order to compare T cell responses in the lung and blood. The BAL cells
were centrifuged at 485 g and washed with medium. 2–300 000
PBMC/BAL cells were placed in individual wells of IFN-g ELISPOT
plates and studied as described above. Additional aliquots of PBMC
and BAL cells were stained for surface expression of CD3, CD4, CD8,
CXCR3 and a4b1, analyzed by flow cytometry and Flow Jo software.
Transcriptomal analyses. To perform a preliminary study of the
molecular signatures of CD4þ T cells induced by ID vs. PO BCG
vaccination,we purifiedCD4þ TcellswithMiltenyi immunomagnetic
beads and prepared dendritic cells (DC) for use as antigen presenting
cells as described previously.26 We purified CD4þ T cells from PBMC
harvested before vaccination (naı¨ve control samples), 7 days after
vaccination (representing the peak of T cell activation after BCG
in vivo) and 56 days after vaccination (representing an early memory
time point of BCG immunity). Autologous DC were infected or not
with Danish BCG (MOI of 20) and then co-cultured overnight with
CD4þ T cells purified from pre- and post-vaccination PBMC. RNA
was extracted the next day with RNAeasy Mini Kit (Qiagen, Valencia,
CA, USA). Therefore, 6 RNA samples were studied for each volunteer
individually. Illumina Bead Arrays were used to generate CD4
transcriptomes within the high throughput Microarray Core at
Washington University. Data were normalized and studied with
GenePattern and GSEA to compare pre- and post-vaccination
transcriptomes directly ex vivo and after BCG in vitro re-stimula-
tion.27,28 The differential analysis was done by Compar-
ativeMarkerSelection v10, and two-sided T tests with 10 000
permutations were used to identify gene expressions.
PPD-specific DTH responses. To measure PPD-specific DTH
responses 2 years after BCG vaccination, 5 TU of Tubersol was applied
intradermally and mm of induration measured 48–72 h later.
Statisticalanalyses. Statistical analyseswere performedby theEMMES
Corporation. TheWilcoxonmatchedpairs non-parametric test was used
to compare pre- to post-vaccination responses. Fisher’s exact tests were
used to compare proportions of positive responses and the Mann–
Whitney U test was used to compare responses between groups. Sta-
tistical analyses were performed using SAS version 9.3 software (2011
SAS Institute Inc., Cary, NC).
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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